Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer
W R Bezwoda1, C S Hesdorffer, R D Dansey
1Department of Medicine, University of the Witwatersrand, Johannesburg.
Abstract:
Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer. The first combination, consisting of methotrexate, mitoxantrone (Novantrone) and 5-fluoro-uracil (MNF), gave a response rate of 17/48 (35%). Cyclophosphamide + mitoxantrone (CN) gave a response rate of 20/31 (64%) while cyclophosphamide + mitoxantrone + vincristine (CNV) gave a response rate of 28/39 (72%). The response durations for the three regimens were 6 months for MNF, 7.5 months for CN and 11.5 months for CNV. The regimens were well tolerated with an approximately equal frequency of side-effects. Cardiotoxicity was infrequent, occurring in only 2 patients out of 118 studied.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
